Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox
← Back to News

EMA Recommends Gazyvaro for Systemic Lupus Erythematosus: What the Trial Shows

J

By João L. Carapinha

November 17, 2026

Clinical Practice
Hospital day room with a wide window overlooking a garden with flowering trees

The European Medicines Agency has recommended extending the use of Gazyvaro (obinutuzumab) to treat adults with moderate to severe, active systemic lupus erythematosus (SLE). The recommendation came from the CHMP meeting of 9 to 12 November 2026, and EMA published it on 13 November.

Gazyvaro would be added to standard therapy for patients who test positive for certain antibodies and whose disease stays active despite that treatment. EMA does not name the antibodies in its announcement.

Trial results in systemic lupus erythematosus

The recommendation rests on one randomised, double-blind study of 303 adults with active SLE. Patients received Gazyvaro or placebo on top of standard treatment. The primary endpoint was response at 52 weeks on the SLE Responder Index (SRI-4), which means lower disease activity with no worsening and no new organ involvement. Response was 76.7% on Gazyvaro against 53.5% on placebo.

According to EMA, patients on Gazyvaro cut their corticosteroid use while keeping disease under control, and they had fewer flares. The most frequently reported side effects were upper respiratory tract infections and urinary tract infections.

The sponsor, Roche, reports more detail than the EMA announcement. Its release gives an adjusted difference of 23.1% on the SRI-4 endpoint (95% confidence interval 12.5 to 33.6, p<0.001). Under the DORIS definition of remission, remission rates were 33.8% on Gazyvaro against 13.8% on placebo. Roche also says the US Food and Drug Administration accepted a supplemental Biologics License Application for SLE earlier this year.

What happens next

The CHMP opinion is an intermediate step. It goes to the European Commission, which decides whether to extend the EU-wide marketing authorisation. Price and reimbursement for the new use will be decided in each Member State, taking into account the role of the medicine in its national health system.

Gazyvaro has been authorised in the EU since July 2014. It is already used for chronic lymphocytic leukaemia, follicular lymphoma and certain forms of lupus nephritis.

Why it matters for market access

Each national assessor will have to judge Gazyvaro against current care for SLE. The comparator and the corticosteroid-sparing effect are the points most likely to be tested. Syenza News has looked at the economics of SLE treatment before, in its review of anifrolumab, which covered the disease’s burden on health systems.

Immunology is also a crowded field. The EULAR 2026 congress showcased a wide set of autoimmune programmes, and safety remains a live question for newer autoimmune therapies, as the autoimmune CAR-T trial pauses showed.

Source: European Medicines Agency, EMA recommends extending Gazyvaro’s use to systemic lupus erythematosus, 13 November 2026; Roche media release, 13 November 2026.

Let Google know we are your trusted source.

Add our editorial as a preferred source in your search results.

Trust this Source

Value Science Weekly

The week in health technology assessment, market access and health economics — what moved, and what it means.

You can unsubscribe at any time. Read our privacy policy.

About this newsletter →